Published online Nov 27, 2026. doi: 10.4254/wjh.126177
Revised: September 4, 2026
Accepted: October 14, 2026
Published online: November 27, 2026
Processing time: 114 Days and 22 Hours
The randomized controlled trial by Mei et al, published in the World Journal of Gastroenterology, investigated a home-based health management program based on timeliness-incentive theory (TIT) for metabolic dysfunction-associated steatotic liver disease. The trial reported improvements in hepatic steatosis, metabolic profiles, and health behaviors, with a high retention rate. The program used four incentive levers: emotional, need-based, role model, and benefit-motivation. Within the benefit-motivation lever, participants who met monthly exercise targets received complementary assessments at no cost. Two of these items constituted diagnostic monitoring, namely hepatic ultrasonography and liver-fibrosis evaluation; the rest are health-feedback components, namely body composition analysis, physical-fitness testing, and dietary-plan revision. Both arms underwent hepatic ultrasonography at baseline and at the 7-month endpoint as the primary outcome. However, additional complementary surveillance, was offered only to the intervention arm and only to compliant participants. Because this surveillance constituted a material incentive and was not offered to controls, incentive and surveillance overlap rather than being mutually exclusive. The design therefore does not allow the observed benefits to be attributed separately to TIT, intensified monitoring or their combination. The report does not specify how often these assessments were delivered, when they were offered relative to compliance milestones, or how many participants received them. Attention-matched controls or multiphase optimization strategy factorial designs, combined with prospective recording of contact frequency and awareness of fibrosis status, would help isolate the active components.
Core Tip: This letter examines the timeliness-incentive home-based metabolic dysfunction-associated steatotic liver disease trial by Mei et al. The intervention bundled psychological incentives with added diagnostic surveillance, which constituted a material reward. These two components therefore overlap, so the benefit cannot be attributed to the theory alone. We recommend attention-matched controls, multiphase optimization strategy factorial designs, and prospective recording of contact frequency and patients’ awareness of fibrosis status. Because the same overlap recurs in multicomponent behavioral and digital interventions, the lesson extends beyond this trial.